An ongoing anti-corruption campaign and the weakness of the Chinese yuan against the US dollar turned out to be two major overhangs for multinationals’ third-quarter financial performance in China, major companies’ results showed.
AstraZeneca PLC’s revenue from China fell 6% year-over-year to $1.5bn in the three months ended 30 September. Excluding foreign...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?